All PlansCoverageHigh impact
Diabetes Tests, Programs and Supplies (CPB 0070, reviewed 2026-02-20)
Aetna·Endocrinology, Pediatrics, Family Medicine +2 more·Medical Policy
Effective date
Feb 20, 2026
We identified it
Aug 14, 2026
Summary
Aetna updated its diabetes testing, programs, and supplies policy (CPB 0070) effective 2026-02-20. Key changes include clarified coverage criteria for continuous glucose monitoring (CGM) devices with specific requirements for intensive insulin regimens, expanded coverage for flash glucose monitoring and implantable glucose sensors as equivalent alternatives, and confirmation of non-covered convenience items (I-Port, hypoglycemic wristbands, cellular glucometry features). Billing teams must verify patient eligibility criteria before processing claims for CGM devices and diabetes supplies.
Action Required
By 2026-02-20, Billing team must: (1) Update billing system with CGM coverage criteria - claims require documentation that patient uses intensive insulin regimen (3+ daily injections or pump therapy) AND meets one of: age <18, not meeting glycemic targets, or experiencing hypoglycemia; (2) For continuation of CGM therapy, verify member has improved glycemic control, decreased hypoglycemia, or 6-month prescriber assessments documented; (3) Ensure diabetic supplies (alcohol swabs, lancets, test strips, glucose monitors, insulin pens, needles, syringes, urine test tablets) are billed as covered without additional authorization; (4) Flag and deny claims for non-covered items: I-Port Injection Port, hypoglycemic wristband alarms (e.g., Sleep Sentry), combination devices (glucose monitor + BP monitor), and cellular glucometry features; (5) Update denial templates to reference CPB 0070 for non-covered convenience items; (6) Educate providers that GAD autoantibodies testing is covered only for type 1 vs type 2 diabetes differentiation with ambiguous history or for stiff-person syndrome diagnosis - deny for all other indications as experimental. Failure to apply these criteria will result in inappropriate claim approvals or denials and potential member disputes.